Steady infusion reduces off periods
- Trial ID
- NCT06937034
- Official Title
- Observational Retrospective CoHort Study on Practical ExperienceS of Treatment With Foslevodopa/foScaRbidopa in Advanced Parkinson's Disease
- Goal
- Steady infusion reduces off periods
- Status
- RECRUITING
- Sponsor
- AbbVie
- Study Type
- OBSERVATIONAL
- Enrollment
- 2000 participants
- Conditions
- Parkinson's Disease
Plain-Language Summary
The goal is to collect real-world, practical experience with continuous subcutaneous foslevodopa/foscarbidopa for people with advanced Parkinson's who have troublesome motor fluctuations and off periods on oral levodopa. The work is a retrospective look at patients treated in routine care, and the medication consists of prodrugs that are converted into levodopa and carbidopa after infusion, delivering steady levodopa levels through a small pump to smooth on/off swings and often reduce the need for frequent oral levodopa doses. Eligible participants are adults 18 and older with levodopa-responsive idiopathic Parkinson's who were prescribed the LDp/CDp continuous subcutaneous infusion and enrolled in the AbbVie Patient Support Program.
Locations
- Medizinische Universitaet Graz /ID# 278569, Graz, Styria, Austria
- Medisch Spectrum Twente /ID# 276695, Enschede, Overijssel, Netherlands
- Universitatea De Medicină Și Farmacie Victor Babeș /ID# 276720, Timișoara, Timiș County, Romania
- Karolinska University Hospital Solna /ID# 277116, Solna, Stockholm County, Sweden
Frequently Asked Questions
- What is this trial testing?
- This trial is studying an experimental treatment. The goal is to collect real-world, practical experience with continuous subcutaneous foslevodopa/foscarbidopa for people with advanced Parkinson's who have troublesome motor fluctuations and off periods on oral levodopa. The work is a retrospective look at patients treated in routine care, and the medication consists of prodrugs that are converted into levodopa and carbidopa after infusion, delivering steady levodopa levels through a small pump to smooth on/off swings and often reduce the need for frequent oral levodopa doses. Eligible participants are adults 18 and older with levodopa-responsive idiopathic Parkinson's who were prescribed the LDp/CDp continuous subcutaneous infusion and enrolled in the AbbVie Patient Support Program.
- Who can participate?
- Participants must be at least 18 Years.
- Where is this trial located?
- This trial is recruiting at 4 locations.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 8 months.